Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06978478 | An Imaging Study in ER Negative Breast Cancer by Targeting αvβ6(IMETAB6) | withdrawn | N/A | 0 | Queen Mary University of LondonOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT01349088 | Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 |
| May 2, 2025 |
| clinicaltrials |
| NCT04418219 | Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06938711 | A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Context Therapeutics Inc.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05940844 | Study of OB-002 in Patients With Refractory Metastatic Cancer | withdrawn | Phase 1 | 0 | Orion Biotechnology Polska Sp. z o.o.INDUSTRY | 0 | Apr 9, 2025 | clinicaltrials |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer | withdrawn | — | 0 | PfizerINDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT03175666 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03554109 | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine(TNBC) | withdrawn | Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05554211 | Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05539365 | Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06341647 | Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | withdrawn | Phase 1 | 0 | GC Cell CorporationINDUSTRY | 0 | Jan 24, 2025 | clinicaltrials |
| NCT03473691 | Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer(Breast50) | withdrawn | Early Phase 1 | 0 | University of VirginiaOTHER | 0 | Dec 9, 2024 | clinicaltrials |
| NCT02883361 | Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors(MI for AIs) | withdrawn | Phase 2 / Phase 3 | 0 | University of CalgaryOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04160182 | Feasibility and Effectiveness of an Internet-based Intervention to Manage Fatigue in Breast Cancer Survivors | withdrawn | N/A | 0 | University of Toledo Health Science CampusOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04232319 | Feasibility and Effectiveness of a Sleep Hygiene Education Program for Sleep Issues in Breast Cancer Survivors | withdrawn | N/A | 0 | University of Toledo Health Science CampusOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05427344 | Effectiveness of Aquatic Exercise on Fatigue, Neuropathy and Quality of Life Among Cancer Patients | withdrawn | N/A | 0 | Tel Aviv UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT04007549 | Brief Intervention for Tobacco and Alcohol Risk Reduction for Couple During Breast Cancer Treatment.(IBMC) | withdrawn | N/A | 0 | Institut BergoniéOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05177796 | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT05488444 | A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted Intervention Using Patient Navigators or Routine Clinical Care | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT03238053 | Laser Treatment of Genito-urinary Syndrome in Women | withdrawn | N/A | 0 | Herning HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | withdrawn | Phase 1 | 0 | Brown UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06105008 | Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | RemeGen Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT04205786 | Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05672342 | Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04880369 | Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease Progression and Gene Expression(DAGMAR) | withdrawn | N/A | 0 | Danish Cancer SocietyOTHER | 0 | Aug 7, 2024 | clinicaltrials |
| NCT05039931 | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors | withdrawn | Phase 1 | 0 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT04584775 | Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care | withdrawn | N/A | 0 | Medical University of GrazOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT02407613 | Efficacy of MR-HIFU Ablation of Breast Cancer | withdrawn | N/A | 0 | UMC UtrechtOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06057636 | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | withdrawn | N/A | 0 | The University of Tennessee, KnoxvilleOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT05073172 | StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients | withdrawn | N/A | 0 | OHSU Knight Cancer InstituteOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT04136496 | Evaluation of a Novel Axillary Lymph Node Ink Localization Technique: A Feasibility Study | withdrawn | N/A | 0 | The Ottawa HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06137651 | Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT05967286 | Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Mar 20, 2024 | clinicaltrials |
| NCT03841747 | Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer(PELICAN) | withdrawn | Phase 2 | 0 | Queen Mary University of LondonOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT04102436 | Non-Viral TCR Gene Therapy | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05689359 | Evaluation of Hydroxychloroquine to Prevent CIPN | withdrawn | Phase 2 | 0 | University of ArizonaOTHER | 0 | Mar 8, 2024 | clinicaltrials |
| NCT04199520 | Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients | withdrawn | Phase 2 | 0 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04770714 | Prospective Comparison of Breast MRI vs Contrast Mammography Prior to Surgery in Breast Cancer Patients | withdrawn | N/A | 0 | University of ArizonaOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT05703555 | INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701(INTRUSION) | withdrawn | Phase 2 | 0 | Erasmus Medical CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05474690 | A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer | withdrawn | Phase 3 | 0 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05263648 | Virtual Reality Software to Reduce Stress in Cancer Patients(OU-SCC VR) | withdrawn | N/A | 0 | University of OklahomaOTHER | 0 | Feb 14, 2024 | clinicaltrials |
| NCT04156880 | Artificial Intelligence in Mammography-Based Breast Cancer Screening | withdrawn | — | 0 | Chinese University of Hong KongOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT03981718 | Adipose-Induced Regeneration of Breast Skin to Treat Post-Mastectomy Radiation Injury in Breast Cancer Patients | withdrawn | N/A | 0 | Mayo ClinicOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT05315687 | Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT04756505 | Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 27, 2023 | clinicaltrials |
| NCT05465590 | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer | withdrawn | Early Phase 1 | 0 | Mainline Biosciences, Inc.INDUSTRY | 0 | Dec 21, 2023 | clinicaltrials |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | withdrawn | Phase 1 | 0 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Nov 18, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 18, 2025source: clinicaltrials